Simon TA, Suissa S, Skovron ML, Frisell T, Askling J, Michaud K, Pedro S, Strangfeld A, Meissner Y, Boers M, Hoffman V, Dominique A, Gomez A, Hochberg MC. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024 Feb;64:152313. doi: 10.1016/j.semarthrit.2023.152313
Lennon RP, Demetriou TJ, Khalid MF, Van Scoy LJ, Miller EL, Dong H, Zgierska AE. Characteristics and outcomes among hospitalized COVID-19-positive patients in a nonurban environment. Mil Med. 2021 Nov 2;186(11-12):1088-92. doi: 10.1093/milmed/usab044
Chen ZX, Hohmann L, Banjara B, Zhao Y, Diggs K, Westrick SC. Recommendations to protect patients and health care practices from Medicare and Medicaid fraud. J Am Pharm Assoc. 2020 Nov;60(6):e60-5. doi: 10.1016/j.japh.2020.05.011
Schlatter F, Piquerez A, Habermacher M, Ragettli MS, Roosli M, Brink M, Cajochen C, Probst-Hensch N, Foraster M, Wunderli J-M. Validation of large scale noise exposure modelling by long-term measurements. Noise Mapp. 2017 Dec 22;4:75-86. doi: 10.1515/noise-2017-0006
Thyagarajan (Hoffman) V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012 Dec;42(3):223-33. doi: 10.1016/j.semarthrit.2012.05.004
Alwin J, Brodtkorb T. Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2012;13(1):25-31.
Schwab PE. Tobacco survey results/ cigarette sales in pharmacy: consumer research and analysis to support merchandising decisions. Poster presented at the 2010 American College of Apothecaries Mid-Year Meeting; March 2010. Memphis, TN. [abstract] J Am Pharm Assoc. 2010 Mar; 50(2).
Zaniolo O, Wolowacz SE, Pradelli L. Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.
Zaniolo O, Wolowacz SE, Pradelli L. Economic performance of dabigatran etexilate for primary VTE prevention following total hip and knee replacement surgery in Italy [Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia]. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.
Mehta S, Nagar SP, Aparasu R. Unmet prescription medication need in U.S. children. J Am Pharm Assoc. 2009 Nov;49(6):769-76.
Andrews EB, Gilsenan A, Cook SF. Therapeutic Risk Management Interventions: feasibility and Effectiveness. J Am Pharm Assoc. 2004 Jan 1;44(4):491-500.
Carlson AM, Stockwell-Morris L, Perfetto EM, Appel AM, Gilsenan AW. Quality of sleep in patients with osteoarthritis treated with extended-release and conventional etodolac. J Am Pharm Assoc. 1998 Jan;38(1):31-6. doi: 10.1016/S1086-5802(16)30297-2